Physician profile

Thomas H Sanders

Foot and Ankle Surgery · Falls Church, VA

NPI 1851525364

$41,001.09

in general payments reported to CMS, 2019-2025

30 companies · $1,445 in 2025

The $1,445 reported for 2025 was more than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).

See the full distribution for Foot and Ankle Surgery

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$6,212.50
Travel and Lodging$3,943.40
Food and Beverage$2,843.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Paragon 28, INC. $15,238.91 2019-2021
Medline Industries LP $7,506.75 2022-2025 Medline, Medline Unite, Medline Industries, INC.
Arthrex, INC. $7,126.86 2019-2025 Arthrex
Supreme Orthopedic Systems, LLC $6,121.55 2019-2025
Metric Medical Devices, INC. $1,250.00 2022-2024 Link
Stryker Corporation $664.95 2019-2025 Augment Injectable, Citrefix, Gamma
Ossio INC $640.11 2024
Kci USA, INC. $400.00 2020
Smith+Nephew, INC. $368.34 2022-2025 Grafix, Stravix, Grafix Pl
Integra Lifesciences Corporation $260.49 2019-2025 Integra, Primatrix, Integra Dermal Regeneration Template
Djo, LLC $189.70 2023 Donjoy, Procare, Aircast
Linvatec Corporation $180.22 2022-2023 Allograft Tissue
Organogenesis INC. $167.94 2023-2025 Puraply, Affinity
Convatec INC. $127.46 2023-2025
Medtronic, INC. $115.15 2022-2024 Intellis Adaptivestim
Show all 30 companies
CompanyGeneral paymentsYearsTop products
Zimmer Biomet Holdings, INC. $97.10 2019
Theramicro, INC. $92.15 2025 Tekbrace Solo
Fidia Pharma USA INC. $63.13 2022-2024 Hymovis, Triluron, Hyalgan
Horizon Therapeutics Plc $51.43 2019-2022
Acumed LLC $48.49 2024 Acumed, Osteomed
Amgen INC. $47.00 2024-2025 Krystexxa
Pacira Pharmaceuticals Incorporated $46.89 2025 Zilretta, Exparel
Boston Scientific Corporation $35.98 2025 General - Pain Management
Cashflow Solutions, LLC $30.86 2023-2024 Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White
Abbott Laboratories $27.21 2019
Heron Therapeutics, INC. $26.22 2022
Depuy Synthes Sales INC. $25.18 2023 Va-Lcp
Triad Life Sciences INC. $23.89 2022
Flower Orthopedics Coporation $14.40 2023
Avanos Medical $12.73 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$875.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas H Sanders

$41,001.09

in general payments reported 2019-2025

Years
2019-2025
Top company
Paragon 28, INC.
Context
The $1,445 reported for 2025 was more than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).

https://glasscript.com/doctor/1127818/thomas-h-sanders

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.